Optimal Cytoreductive Surgery Is an Independent Prognostic Indicator in Stage IV Epithelial Ovarian Cancer with Hepatic Metastases
- 1 August 2000
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 78 (2) , 171-175
- https://doi.org/10.1006/gyno.2000.5841
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Survival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian CancerGynecologic Oncology, 1999
- Natural History of Stage IV Epithelial Ovarian CancerJournal of Clinical Oncology, 1999
- Stage IV Ovarian Cancer: Impact of Surgical Debulking1Gynecologic Oncology, 1997
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinomaGynecologic Oncology, 1992
- Meta-analysis of surgery in advanced ovarian carcinoma: Ismaximum cytoreductive surgery an independent determinant of prognosis?American Journal of Obstetrics and Gynecology, 1992
- Primary surgical therapy of ovarian cancer: How much and whenGynecologic Oncology, 1990
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- The changing prognosis and treatment in cancer of the ovaryAmerican Journal of Obstetrics and Gynecology, 1968
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958